Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort.
Supplementary Table S2: Genes analyzed as part of this study.
Supplementary Table S3: Prevalence of alterations in the genes analyzed.
Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies.
Supplementary Table S5: Chromosomal losses and gains in SCLC.
Supplementary Table S6: TET2 loss of function alterations detected in SCLCs.
Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs.
Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors.
Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs.
Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors.
Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy.
Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site.
Supplementary Table S13: Aneuploidy patterns based on site of biopsy.
Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies.
Supplementary Table S15: Comparison of gene alterations in liver and brain metastases.
Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites.
Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort.
Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts.
Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC.
Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors.
Supplementary Table S21: Manual review of specific HPV+ SCLCs.
Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts.
Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts.
Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.